It has nothing to do with the effectiveness of Sinovac’s vaccine.
Limited Efficacy: Malaysia to end Coronavac use
by Focus Team
July 19, 2021
Malaysia’s Ministry of Health has said the country will stop administering Coronavac, a COVID-19 vaccine produced by China’s Sinovac Biotech, as soon as its supplies run out. According to Reuters, the decision came amid evidence that the Chinese vaccine has limited effectiveness against the Delta variant, which is causing outbreaks of the disease in Southeast Asia.
Malaysian Health Minister Adham Baba said the Malaysian government has guaranteed about 45 million doses of the Pfizer/BioNTech vaccine, enough to cover 70% of its population, compared with 16 million doses of Sinovac’s vaccine.
“About half of the 16 million have already been distributed, so the rest will be used to cover the second doses,” said Adham. “For those who have not yet been vaccinated, they will receive the Pfizer vaccine.”
The Malaysian government’s decision comes amid growing concerns about the effectiveness of Chinese vaccines against the more transmissible Delta variant of COVID-19.
Malaysia denies news that it will no longer use Sinovac’s vaccine for efficacy reasons
by Butantan Team
August 03, 2021
In recent days, the Malaysian government has made public announcing that the country intends to stop using the vaccine by Chinese pharmaceutical Sinovac, which in Brazil is produced in partnership with Butantan and called CoronaVac, because the stock of the immunizing agent is coming to an end , and not due to efficiency issues.
On 7/15, the Malaysian Health Minister, Adham Baba, announced that the country would maintain vaccination with Sinovac only in the second dose, as it had increased the stock of doses received from another manufacturer. Days later, Malaysia’s immunization program coordinator, Khairy Jamaluddin, stressed that the decision was due to logistics, not issues involving the effectiveness of the immunizer.
“It has nothing to do with the effectiveness of Sinovac’s vaccine. There has been a lot of speculation about it. It’s because we will receive all of our delivery in late July and early August,” explained Malaysia’s immunization program coordinator, Khairy Jamaluddin . He also stated that if there are problems with the supply of other pharmaceutical companies, more doses of Sinovac’s vaccine could be purchased.
By the first day of August, Malaysia had vaccinated, at least with the first dose, a total of 14.2 million people, about 44% of the total population. Jamaluddin commented at a new press conference that the country’s daily vaccination rate is among the fastest in the world. The minister’s forecast is that 80% of the country will be vaccinated by December.
The efficacy of CoronaVac was proven in Brazil through a phase 3 clinical study with 13,060 volunteers, all health professionals, a population highly exposed to Covid-19. The final results showed that the overall effectiveness of the immunizing agent can reach 62.3% when the interval between the first and second dose of the vaccine is 21 to 28 days. The data were released on The Lancet magazine’s preprint platform and are in the process of peer review.
We strive for accuracy and fairness. If you see something that doesn’t look right, contact us !
Disclaimer for External Links
These links are being provided as a convenience and for informational purposes only; they do not constitute an endorsement or an approval by the BPiero of any of the products, services or opinions of the corporation or organization or individual. The BPiero bears no responsibility for the accuracy, legality or content of the external site or for that of subsequent links. Contact the external site for answers to questions regarding its content.